Evidence map›Paper›PMID 31676945›Full record

ArticleArchives of dermatological research2020

Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma.

Jingkai Xu, He Huang, Shangshang Wang, Yanzhen Chen, Xueli Yin, Xuejun Zhang, Yaohua Zhang

Open access · hybridAbstract read
In one paragraph

Article in Archives of dermatological research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jingkai XuInstitute of Dermatology, Huashan Hospital, Fudan University, 12 Wulumuqi Zhong Road, Jing'an District, Shanghai, 200040, China.
He HuangInstitute of Dermatology, Huashan Hospital, Fudan University, 12 Wulumuqi Zhong Road, Jing'an District, Shanghai, 200040, China.
Shangshang WangInstitute of Dermatology, Huashan Hospital, Fudan University, 12 Wulumuqi Zhong Road, Jing'an District, Shanghai, 200040, China.
Yanzhen ChenWorldwide Medical Center, Huashan Hospital, Fudan University, 12 Wulumuqi Zhong Road, Jing'an District, Shanghai, 200040, China.
Xueli YinDepartment of Dermatology, The First Affiliated Hospital, Anhui Medical University, 81 Meishan Road, Hefei, 230032, China.
Xuejun ZhangInstitute of Dermatology, Huashan Hospital, Fudan University, 12 Wulumuqi Zhong Road, Jing'an District, Shanghai, 200040, China.
Yaohua ZhangInstitute of Dermatology, Huashan Hospital, Fudan University, 12 Wulumuqi Zhong Road, Jing'an District, Shanghai, 200040, China. yvonne_zhang@ymail.com.ORCID http://orcid.org/0000-0002-8737-2012
Ministry of Education of the People's Republic of China · CNFudan University · CN

Funding

Natural Science Foundation of Shanghai 15ZR1405700Young Scientists Fund 81602397
6 · The paper itself

Abstract

Cutaneous T cell lymphoma (CTCL) is a rare but potentially devastating primary cutaneous lymphoma. CTCL is characterized by localization of neoplastic T lymphocytes to the skin, with mycosis fungoides (MF) and its leukemic form, Sézary syndrome (SS) being the most common variants. Thymocyte selection-associated high-mobility group box (TOX) gene has been found to be highly expressed in MF and SS. It is reported that higher expression levels of TOX in patients will increase risks of disease progression and poor prognosis. However, the molecular events leading to these abnormalities have not been well understood. To better understand the molecular mechanism underlying TOX-mediated differentially expressed genes (DEGs) in CTCL, and to identify DEGs pathways triggered after knockdown of TOX gene in the CTCL cell line Hut78, we employed two shRNA-mediated lentiviruses to knock down TOX gene in the skin lymphoma cell line HuT78. RNA sequencing (RNAseq) analysis was applied to analyze DEGs, DEGs GO and their corresponding pathways. Knockdown of TOX can induce upregulation of 547 genes and downregulation of 649 genes, respectively. HOXC9 was the most significant downregulated gene. Most DEGs are enriched in malignancies and relate to the Wnt and mTOR signaling pathways, and therefore they can regulate cellular processes and induce different biological regulation. Transcriptome analysis of DEGs after knockdown of TOX in our study provides insights into the mechanism of TOX in CTCL and suggests candidate targets for therapy of CTCL.

Indexed as

Gene Expression Regulation, NeoplasticBiomarkers, TumorCell Line, TumorDown-RegulationGene Knockdown TechniquesHigh Mobility Group ProteinsHomeodomain ProteinsHumansLymphoma, T-Cell, CutaneousRNA-SeqSkin NeoplasmsUp-RegulationBiomarkers, TumorHigh Mobility Group ProteinsHomeodomain ProteinsHoxc9 protein, humanTOX protein, humanCutaneous T cell lymphomaDifferentially expressed geneRNA sequencing analysisSignaling pathwayTOX

Identifiers

PMID31676945
PMCPMC7354281
OpenAlexW2987982078

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.